SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Business
Cancer Stakeholders Call for Consensus of Terms to Encourage Patients’ Genetic Testing
Cancer patients aren’t getting the testing they need for precision medicine, partially because of pervasive confusion regarding terminology, according to a whitepaper released July 7 by the Consistent Testing Terminology Working Group.
July 10, 2020
 · 
5 min read
 · 
Gail Dutton
Drug Development
Low-Dose Radiation May Lower Inflammation in COVID-19 Patients
Low-dose radiation therapy seems to improve outcomes for COVID-19 patients. At least a dozen clinical trials are underway throughout the world to further explore the benefits.
July 9, 2020
 · 
5 min read
 · 
Gail Dutton
Business
Alzheimer’s Drugs on Verge of Becoming Mainstream Medicine, but Early Intervention Still is Needed
Diagnostics and therapeutics for Alzheimer’s disease are on the verge of becoming mainstream medicine. It’s about time, too.
July 9, 2020
 · 
4 min read
 · 
Gail Dutton
Business
IM Therapeutics Brings First Personalized, Oral Therapy for Insulin Regulation to Clinical Trials
IM Therapeutics is developing a personalized, orally available small molecule therapeutic for diabetes. This is a milestone for autoimmune diseases and may be the first time diabetes patients can be preselected for a therapeutic based on whether they carry a specific gene.
July 7, 2020
 · 
4 min read
 · 
Gail Dutton
Business
AGTC Boosts AAV Manufacturing Productivity with Herpes Simplex Virus
By using the herpes simplex virus (HSV) as a helper for its adeno-associated viral (AAV) platform, Applied Genetic Technologies Corporation (AGTC) created AAVs that are more robust, purer and lower cost than any of the other methods.
July 2, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Strategies to Help You Get the Most Value from Regulatory Affairs Professionals
Meet with regulatory affairs professionals early and often. That’s the message from Neelu Gibson, VP, regulatory affairs, at BD, speaking at Biocom’s June virtual meeting, “Regulatory Affairs…Engagement Do’s & Don’ts.”
July 1, 2020
 · 
5 min read
 · 
Gail Dutton
A New H1N1 Strain From China May Trigger Another Pandemic
Another pandemic may be building in China. This time, it’s a new strain of the H1N1 swine flu and it’s already jumped to humans.
July 1, 2020
 · 
4 min read
 · 
Gail Dutton
Is salt water gargle effective?
Drug Development
Salt Water Gargle Vs. COVID-19: Researchers Launch Study to Lessen Symptoms and Duration of Illness
Salt water gargle is a time-tested way to alleviate sore-throat pain. It can help clear stuffy sinuses. But, is it effective against the symptoms of COVID-19?
June 29, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Draper’s Organ-on-a-Chip Platform Multiplexes Tissue Studies for Coronavirus and Flu
The lung model in Draper’s new organ-on-a-chip platform, PREDICT96, replicates the structure and function of human lung tissue from donors with multiple patient profiles on a 96-well plate, increasing assay throughput by 10-fold.
June 26, 2020
 · 
5 min read
 · 
Gail Dutton
Business
Regenerative Medicine Needs a New, Digital Supply Chain
The supply chain that exists for traditional pharmaceuticals is woefully insufficient for regenerative medicine, according to Robert Lechich, principal manufacturing and supply chain consultant for Global OT/IT – Quality Services.
June 25, 2020
 · 
5 min read
 · 
Gail Dutton
vfCRISPR Uses Light to Bring Precision and Speed to Gene Editing
Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.
June 24, 2020
 · 
3 min read
 · 
Gail Dutton
Business
Drugging the Undruggable: How AI Does the (Almost) Impossible
Artificial intelligence (AI) is amplifying the pace of drug development, allowing developers to attack otherwise intractable problems and achieve results in weeks. Previously, results may have been impossible within any time frame.
June 23, 2020
 · 
4 min read
 · 
Gail Dutton
Drug Development
9 Meters Beats Corporate Competitors to Phase III Celiac Trials
With phase III trials underway and Fast Track designation from the FDA, “It’s, conservatively, at least one year ahead of everyone else’s,” John Temperato, president and CEO, told BioSpace.
June 22, 2020
 · 
4 min read
 · 
Gail Dutton
Business
MMR Vaccine Could Invigorate the Innate Immune System to Fight COVID-19
As companies scramble to develop a vaccine against the SARS-CoV-2 virus, a team of husband and wife researchers have found that the measles, mumps, rubella (MMR) vaccine can reduce the symptoms of COVID-19.
June 22, 2020
 · 
4 min read
 · 
Gail Dutton
Business
UV-C Light Kills SARS-CoV-2, Triggering Novel Lighting Options for Public Spaces
UV-C light has been used as a disinfectant against viruses and bacteria for more than 40 years. Now, researchers at Boston University and Signify (formerly Phillips) have confirmed that it also effectively eradicates the SARS-CoV-2 virus.
June 19, 2020
 · 
3 min read
 · 
Gail Dutton
Load More